Stay updated on SCR-6920 Capsule Safety in Malignant Tumors Clinical Trial
Sign up to get notified when there's something new on the SCR-6920 Capsule Safety in Malignant Tumors Clinical Trial page.

Latest updates to the SCR-6920 Capsule Safety in Malignant Tumors Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe record now presents details for the recruiting Phase 1 study of SCR-6920 in patients with advanced malignant tumors, including eligibility criteria, study design, outcomes, and contact information.SummaryDifference47%

- Check15 days agoChange DetectedThe footer's site revision identifier changed from v3.7.2 to v3.8.0; the page remains a 403 Forbidden error page.SummaryDifference0.2%

- Check22 days agoChange DetectedA sitewide NIH notice was added, announcing updates and FAQs about the transition from “Artificial Intelligence” to “Super Intelligence” terminology.SummaryDifference1%

- Check29 days agoChange DetectedThe footer revision label changed from v3.7.1 to v3.7.2 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check36 days agoChange DetectedThe site revision label in the footer changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check56 days agoChange DetectedThe page now displays a 403 Forbidden error for the study record, preventing access to the study details. The header and footer are visible, but the main content is unavailable.SummaryDifference18%

Stay in the know with updates to SCR-6920 Capsule Safety in Malignant Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SCR-6920 Capsule Safety in Malignant Tumors Clinical Trial page.